Aventis Pharmaceuticals Allegra (Fexofenadine Hcl) 30-Mg tablets now available to treat seasonal allergies, chronic hives in children 6 to 11 years

PARSIPPANY, N.J., June 5, 2000 -- Aventis Pharmaceuticals announced today that Allegra® (fexofenadine HCl) 30-mg tablets, twice daily (BID), are now available by prescription for the relief of seasonal allergic rhinitis (SAR) and chronic idiopathic urticaria (CIU) in children aged 6 to 11 years.

"Seasonal allergies affect up to six million children in the United States," said Eli Meltzer, M.D., of the Allergy and Asthma Group and Research Center, San Diego, California and lead investigator of the clinical study, Safety of Fexofenadine HCl in Children Treated for Seasonal Allergic Rhinitis. "Allegra 30-mg tablets offer physicians a safe, nonsedating allergy treatment that can help in the management of children's seasonal allergies."

In a study of 411 pediatric patients, Allegra 30-mg tablets BID significantly reduced total symptom scores compared to placebo and was well tolerated among children aged 6 to 11 years. Such allergy symptoms, including runny nose, itchy, watery, red eyes, sneezing and itchy nose, palate and throat can hinder the enjoyment of outdoor activities that children like to pursue.

Allegra 30-mg tablets are nonchewable and are smaller than a chocolate chip. This pediatric dose is an addition to the Allegra family of products currently available for patients 12 and older, including Allegra® (fexofenadine HCl) 60-mg capsules, Allegra-D® (fexofenadine HCl 60 mg/pseudoephedrine HCl 120 mg) Extended-Release Tablets and Allegra® (fexofenadine HCl) 180-mg tablets.

Side-Effect Profile
In clinical trials, adverse events with Allegra 30-mg tablets were similar to placebo. The most commonly reported with Allegra 30-mg tablets and placebo in seasonal allergic rhinitis patients 6-11 years are headache (7.2% vs. 6.6%), upper respiratory tract infection (4.3% vs. 1.7%), coughing (3.8% vs. 1.3%), and accidental injury (2.9% vs. 1.3%).

Allegra 60-mg capsules are well tolerated with side effects similar to placebo.

Contact: Charles F. Rouse III
Porter Novelli

Page: 1 2 3

Related medicine news :

1. Aventis Pasteur ready to meet nations needs for tetanus and diphtheria vaccine
2. Aventis Pasteur donates approximately 75 to 90 million doses of smallpox vaccine to the U.S.
3. Aventis Pasteur statement on HVTN 501 decision
4. Millennium, Aventis Pharma form novel alliance
5. Eyetech Pharmaceuticals, Inc. announces macugen data on treating macular degeneration
6. MetaPhore Pharmaceuticals initiates Phase I clinical trial of enzyme mimetic compound for oncology
7. Maret Pharmaceuticals presents promising Phase I/II clinical MARstem™ results at international symposium on new drugs in cancer therapy
8. NIH awards grant to MetaPhore Pharmaceuticals to study novel pain treatments
9. Pharmaceuticals and personal care products
10. Nortran Pharmaceuticals Inc. and Hoechst Marion Roussel announce collaborativeagreement
11. Signal Pharmaceuticals Announces Positive Results In Preclinical Study Of Novel Drug Leads For Treatment Of Osteoporosis

Post Your Comments:

(Date:2/19/2019)... ... February 19, 2019 , ... In one ... pregnant and postpartum women, a team led by a Worcester Polytechnic Institute professor ... show increased depressive symptoms, greater weight gain during pregnancy, and weight retention after ...
(Date:2/19/2019)... ... February 19, 2019 , ... Pneumatic Vacuum Elevators, LLC ... provide information on how-to make a house handicap accessible. , With this ... make a house handicap accessible. To accurately educate consumers on handicap accessibility, ...
(Date:2/19/2019)... ... February 19, 2019 , ... Hospice of Westchester (HOW) ... The funds will support the heart of its operation, the organization’s Home Care Services. ... years, and we are grateful for their ongoing generosity,” said Mary K. Spengler, MS, ...
(Date:2/19/2019)... ... 2019 , ... The California Dental Association is pleased to ... as a new member benefit. , Student loan debt is one of ... all indebted graduates in the class of 2018 for public and private dental ...
(Date:2/19/2019)... YORK (PRWEB) , ... February 19, 2019 , ... ... Dave,” a cancer survivor and well-respected advocate for patient engagement, will deliver the ... Business Conference. deBronkart brings critical awareness of participatory medicine and empowering partnerships between ...
Breaking Medicine News(10 mins):
(Date:2/19/2019)... ... , ... Mothers’ Milk Bank of North Texas (MMBNT) has moved ... for the nonprofit. , The building in southwest Fort Worth features three times the ... health and survival of premature and critically ill infants through the safe provision of ...
(Date:2/19/2019)... ... , ... John M. Memory, Ph.D., J.D. , is the author of ... in a University or College Course” (published by Archway Publishing). Memory has concluded that ... undergraduate courses of a major university in the U.S. Southeast. Memory contends these conclusions ...
(Date:2/19/2019)... ... 2019 , ... As one of Delaware’s most-esteemed living artists, fine-arts painter Rick Phillips ... paint, it’s not work,” he said. “You get that feeling in your belly, this is ... Fine art has also given the former commercial artist a serenity and fulfilment he hopes ...
Breaking Medicine Technology:
Cached News: